Latest Breaking News On - Prodrug plus chemoradiation - Page 1 : comparemela.com

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma after experimental treatment with CAN-2409 Estimated overall.

United statesGroot koerkampGarrett nicholsAljanae reynoldsSylvia wheelerCompany nasdaqSociety for immunotherapyNational cancer instituteCandel therapeutics incProdrug plus chemoradiationBorderline resectableChief medical officerPaul peter takChief executive officerNon metastatic pancreaticEnd results

Candel Therapeutics (CADL) Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics (CADL) Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Garrett nicholsCompany nasdaqSociety for immunotherapyCandel therapeutics incCandel therapeuticsProdrug plus chemoradiationBorderline resectableChief medical officerPaul peter takChief executive officer

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesGroot koerkampSylvia wheelerAljanae reynoldsGarrett nicholsCompany nasdaqSociety for immunotherapyCandel therapeutics incNational cancer instituteRandomized phaseNon metastatic pancreaticProdrug plus chemoradiationBorderline resectableChief medical officerPaul peter takChief executive officer

Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting

One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation.

San diegoUnited statesSan diego convention centerAljanae reynoldsFrancesca baroneGarrett nicholsSylvia wheelerUniversity of pennsylvania centerSociety for immunotherapy of cancerCandel therapeutics incDrug administrationAnnual meetingPresentation titleProdrug plus chemoradiationBorderline resectableChief medical officer

Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting

Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual Meeting
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

San diego convention centerUnited statesSan diegoGarrett nicholsAljanae reynoldsFrancesca baroneSylvia wheelerUniversity of pennsylvania centerDrug administrationCandel therapeutics incSociety for immunotherapy of cancerDiscovery platformCandel therapeuticsAnnual meetingPresentation titleProdrug plus chemoradiation